Abstract 13642: Post-Operative Bleeding Risk in TAVR Patients With Atrial Fibrillation

• Published in: Circulation (New York, N.Y.) N.Y.), 2022-11, Vol.146 (Suppl_1), p.A13642-A13642
• Main Authors: Brahier, Mark S, Kochi, Shwetha, Riskin, Jeffrey, Kopera, Ann, Lawrence, Luke, Patel, Jay B, Thomaides, Athanasios X, Waksman, Ron, Satler, Lowell, Srichai, Monvadi B, Vargas, Jose D
• Format: Article
• Language: English
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/circ.146.suppl_1.13642

IntroductionAntithrombotic medications are the subject of multiple transcatheter aortic valve replacement (TAVR) randomized control trials. Pragmatically, decisions are complicated by conditions such as atrial fibrillation (AF) that also require lifetime anticoagulation. Our study examines antithrombotic medications in a real-world cohort to identify risk factors for bleeding by 1-year post-TAVR. MethodsThis retrospective study includes 844 patients undergoing transfemoral TAVR between 2015 and 2020. Pre- and post-operative medications, comorbidities, and 1-year outcomes were recorded based on review of the medical record. Antithrombotic regiment decisions were made on a case-by-case basis. Bleeding classification followed VARC2 definitions. Patients were stratified into two groups based on history of AF. Multivariable logistic regression was used to determine independent predictors of bleeding. ResultsAmong the 844 patients, 290 had comorbid AF (34%). Patients with AF were older (80.3 vs 77.8 years; p